Changing myelofibrosis's natural course at last

Blood

Volumn 123, Issue 12, 2014, Pages 1776-1777

  Verstovsek, Srdan ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; FEDRATINIB; JANUS KINASE 2; RUXOLITINIB; STAT PROTEIN;

CLINICAL FEATURE; DISEASE COURSE; DRUG EFFICACY; DRUG RESPONSE; ENZYME INHIBITION; GENE MUTATION; HUMAN; MYELOFIBROSIS; NOTE; PRIORITY JOURNAL; SPLENOMEGALY; SURVIVAL TIME;

FEMALE; HUMANS; MALE; PRIMARY MYELOFIBROSIS; PYRAZOLES;

EID: 84897509815     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-01-551267     Document Type: Note

References (10)

1. Passamonti F, Maffioli M, Cervantes F, et al. Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts. Blood. 2014;123(12):1833-1835.
2. Mascarenhas J, Mughal TI, Verstovsek S. Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib. Curr Med Chem. 2012;19(26):4399-4413.
3. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelo fibrosis based on a study of the International Working Group for Myelo fibrosis Research and Treatment. Blood. 2009;113(13):2895-2901.
4. Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369(25):2391-2405.
5. Cervantes F, Vannucchi AM, Kiladjian JJ, et al; COMFORT-II investigators. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood. 2013;122(25):4047-4053.
6. Thiele J, Bueso-Ramos CE, Sun W, et al. Effects of five-years of ruxolitinib therapy on bone marrow morphology in patients with myelo fibrosis and comparison with best available therapy [abstract]. Blood. 2013;122(21): Abstract 4055.
7. Tefferi A, Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol. 2011;29(10):1356-1363.
8. Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010;363(12):1117-1127.
9. Pardanani AD, Jamieson CHM, Gabrail NY, et al. Updated results from a randomized phase II dose-ranging study of the JAK2-selective inhibitor SAR302503 in patients with myelo fibrosis (MF). J Clin Oncol. 2013;31(Suppl):7109.
10. Mascarenhas J, Hoffman R. A comprehensive review and analysis of the effect of ruxolitinib therapy on the survival of patients with myelofibrosis. Blood. 2013;121(24):4832-4837.